TCTR20210203001招募中2 期
Efficacy of intranasal fluticasone furoate for prevention chronic rhinosinusitis in nasopharyngeal carcinoma patient: A randomized controlled trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •Nasopharyngeal carcinoma patients age > 18 years who just got the diagnosis and will start radiotherapy
排除标准
- •1. patients who has sinus surgery before
- •2. patients with rhinosinusitis infection in the past 6 months
- •3. patients who has been using intranasal corticosteroids before
研究者
相似试验
进行中（未招募）
1 期
A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal allergiesEUCTR2015-004885-27-Outside-EU/EEAGlaxoSmithKline Research & Development Ltd936
已完成
1 期
Effects of fluticasone nasal spray on clinical symptoms and serum IgENasal polypIRCT20140519017756N40Mashhad University of Medical Sciences34
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDEUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000